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Abstract
Introduction: Fatigue is one of the most disabling symptoms associated with fibromyalgia that greatly impacts
quality of life. Fatigue was assessed as a secondary objective in a 2-phase, 24-week study in outpatients with
American College of Rheumatology-defined fibromyalgia.
Methods: Patients were randomized to duloxetine 60-120 mg/d (N = 263) or placebo (N = 267) for the 12-week
acute phase. At Week 12, all placebo-treated patients were switched to double-blind treatment with duloxetine for
the extension phase. Fatigue was assessed at baseline and every 4 weeks with the Multidimensional Fatigue
Inventory (MFI) scales: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Activity, and Reduced Motivation.
Other assessments that may be associated with fatigue included Brief Pain Inventory (BPI) average pain, numerical
scales to rate anxiety, depressed mood, bothered by sleep difficulties, and musculoskeletal stiffness. Treatment-
emergent fatigue-related events were also assessed. Changes from baseline to Week 12, and from Week 12 to
Week 24, were analyzed by mixed-effects model repeated measures analysis.
Results: At Week 12, duloxetine versus placebo significantly (all p < .05) reduced ratings on each MFI scale, BPI
pain, anxiety, depressed mood, and stiffness. Improvement in ratings of being bothered by sleep difficulties was
significant only at Weeks 4 and 8. At Week 24, mean changes in all measures indicated improvement was
maintained for patients who received duloxetine for all 24 weeks (n = 176). Placebo-treated patients switched to
duloxetine (n = 187) had significant within-group improvement in Physical Fatigue (Weeks 16, 20, and 24); General
Fatigue (Weeks 20 and 24); Mental Fatigue (Week 20); and Reduced Activity (Weeks 20 and 24). These patients also
experienced significant within-group improvement in BPI pain, anxiety, depressed mood, bothered by sleep
difficulties, and stiffness. Overall, the most common (> 5% incidence) fatigue-related treatment-emergent adverse
events were fatigue, somnolence, and insomnia.
Conclusions: Treatment with duloxetine significantly improved multiple dimensions of fatigue in patients with
fibromyalgia, and improvement was maintained for up to 24 weeks.
Trial registration: ClinicalTrials.gov registry NCT00673452.
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Fibromyalgia is a chronic pain disorder that has been
estimated to affect as many as 5 million individuals in the
US, most of whom are women [1]. In addition to wide-
spread pain, symptoms that may include sleep distur-
bances, fatigue, depression, anxiety, and problems with
memory and concentration characterize fibromyalgia
[2-4]. Among these, fatigue greatly impacts quality of life
and has been identified as one of the most disabling
symptoms associated with fibromyalgia [4]. Individuals
with fibromyalgia report that their fatigue typically is not
alleviated by sleep or rest [5] but is a physical tiredness,
and these people have low energy and require increased
effort to overcome inactivity and perform physical tasks
[4,6]. Patients with fatigue report having decreased men-
tal endurance and slowed thinking and feel overwhelmed
[4]. Symptoms of fibromyalgia that may contribute to
fatigue include pain [6-8], stiffness [8], sleep quality [6-9],
and depression [6,7,10].
Medications currently approved for the management of
fibromyalgia include duloxetine hydrochloride (hereafter
referred to as duloxetine), pregabalin, and milnacipran.
Duloxetine is a potent serotonin and norepinephrine reup-
take inhibitor that has been approved by the US Food and
Drug Administration for treatment of major depressive
disorder (MDD) and generalized anxiety disorder (GAD)
and for the management of pain associated with diabetic
peripheral neuropathy, management of chronic musculos-
keletal pain, and management of fibromyalgia. In past
trials in fibromyalgia, the efficacy of duloxetine versus
placebo on improvement in secondary measures of fatigue
has not been consistent. Two of the fibromyalgia trials
assessed fatigue as a secondary outcome by using the
Multidimensional Fatigue Inventory (MFI) [11], which
measures multiple domains of fatigue on five scales:
General Fatigue, Mental Fatigue, Physical Fatigue,
Reduced Activity, and Reduced Motivation. One of the
studies reported significant between-treatment differences
in only Mental Fatigue at the end of 6 months of treat-
ment with duloxetine 60 to 120 mg given once daily (QD)
[12]. The other study reported significant between-treat-
ment differences in improvement with duloxetine 60 mg
QD in Reduced Motivation at the 12-week endpoint and
in Mental Fatigue at both the 12- and 24-week endpoints.
In the same study, treatment with duloxetine 120 mg QD
compared with placebo was associated with significant
improvement in Reduced Motivation by 12 weeks and in
Physical Fatigue, Mental Fatigue, Reduced Motivation, and
Reduced Activity after 6 months of treatment [13].
More recently, treatment with duloxetine 60 to 120 mg
QD for 12 weeks in comparison with placebo was found
to significantly improve fatigue on each MFI domain
[14]. In this secondary analysis, we report monthly
changes in fatigue domains and in symptoms that may be
related to or may contribute to fatigue, such as pain,
d e p r e s s e dm o o d ,a n x i e t y ,s l e e p ,a n ds t i f f n e s sa c r o s st h e
entire study. In addition, changes in MFI scales were
assessed in subgroups of patients who were pain respon-
ders, those who reported ‘feeling much better’,a n dt h o s e
who required a dose escalation in the acute phase. The
current analyses were performed to better characterize
improvement in fatigue during the entire 24 weeks of the
study.
Materials and methods
Details of the 12-week acute phase of the study (F1J-
US-HMGB; trial registration NCT00673452) have been
published [14]. Briefly, this was a 24-week, multicenter,
randomized, double-blind, placebo-controlled trial in
outpatients who were at least 18 years old and who had
fibromyalgia as defined by the American College of
Rheumatology. The purpose of the trial was to confirm
the efficacy of flexibly dosed duloxetine 60 to 120 mg
QD on patient-rated improvement in fibromyalgia. Dou-
ble-blind dose adjustments via an interactive voice
response system were allowed for patients who were
not responding. Response was defined as an at least
50% reduction in pain as assessed by the Brief Pain
Inventory (BPI) [15] 24-hour average pain item (referred
to hereafter as BPI average pain). At weeks 4 and 8,
non-responding patients in the duloxetine group had
their dose increased from 60 to 90 mg QD. At week 8,
patients who were not responding to 90 mg had their
dose increased to 120 mg QD. If the patient could not
tolerate the dose increase, it was reduced to the pre-
escalation dose. After week 12, all patients remained on
their current dose of duloxetine for the remainder of
the study. Patients in the placebo group were transi-
tioned to double-blind active treatment with duloxetine
60 mg QD after week 12.
Efficacy measures in this analysis were assessed at each
study visit, which occurred every 4 weeks, and included
the MFI, BPI average pain, and numerical rating scales
assessing anxiety, mood, ‘bothered by sleep difficulties’,
and musculoskeletal stiffness and Patient Global Impres-
sion of Improvement (PGI-I) [16]. The MFI scales each
rate symptoms from 4 (low) to 20 (high). The BPI average
pain item assesses pain with ratings from 0 (no pain) to 10
(pain as severe as you can imagine). The PGI-I is a catego-
rical scale that patients use to rate their overall impression
of how they are feeling since treatment began; ratings on
the scale are as follows: 1 = very much better, 2 = much
better, 3 = a little better, 4 = no change, 5 = a little worse,
6 = much worse, and 7 = very much worse. The numerical
rating scales assessed patient-perceived severity of anxiety,
mood, ‘bothered by sleep difficulties’, and musculoskeletal
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ered by’)t o1 0( ‘extremely’).
Response to treatment in the acute phase was defined
as an at least 50% reduction from baseline in BPI aver-
age pain severity. Treatment-emergent adverse events
were assessed for the incidence of events that might be
associated with fatigue.
Statistical analyses were done on an intent-to-treat
basis. All randomly assigned patients with a baseline
visit and at least one post-baseline visit were included in
the efficacy analyses, and all randomly assigned patients
were included in the safety analyses. For the acute
phase, these analyses included baseline to week 12. The
extension-phase analyses used week 12 as the baseline
and week 24 as the endpoint. All tested hypotheses were
considered statistically significant if the two-sided P
v a l u ew a sn o tm o r et h a n0 . 0 5( u n l e s so t h e r w i s es p e c i -
fied). P values are provided where valid statistical infer-
ences can be made.
A restricted maximum likelihood-based MMRM
(mixed-effects model repeated measures) analysis was
used on longitudinal changes from baseline for continu-
ous efficacy measures. The model included the fixed
categorical effects of treatment, investigator, visit, and
treatment-by-visit interaction as well as the continuous,
fixed covariates of baseline score and baseline score-by-
visit interaction. An unstructured covariance matrix was
used to model the within-patient errors. Significance
tests were based on least-squares means and type III sum
of squares. Efficacy results presented here are from the
MMRM analysis unless otherwise noted. Last observation
carried forward (LOCF) changes from baseline to end-
point were analyzed by using an analysis of covariance
(ANCOVA) model with the terms of treatment, investi-
gator, and baseline scores. The term ‘mean’ refers to the
least-squares mean, which is the estimated mean from a
specific model (MMRM or LOCF ANCOVA).
Subgroup analyses were conducted on acute-phase
mean changes in MFI scale ratings in pain responders
and non-responders, patients with endpoint PGI-I of
not greater than 2 or greater than 2, and before and
after dose escalations in the acute phase. The models
included baseline, treatment, investigator, subgroup, and
treatment-by-subgroup interaction. Statistical analyses
were performed with SAS software (SAS Institute Inc.,
Cary, NC, USA).
Results
A description of the patient population and the acute-
phase results have been reported previously [14] and
will be briefly summarized here. Overall, most of the
patients (93.2% of 530) were women who were middle-
aged (50.2 ± 11.1 years old) Caucasians (77.4%) or His-
panics (15.7%). About 18% of the study population had
a diagnosis of comorbid current MDD, and about 8%
had a diagnosis of comorbid current GAD. At the
acute-phase baseline, patients reported having moderate
to severe fatigue symptoms, moderately severe pain, and
musculoskeletal stiffness and being bothered by sleep
difficulties. Severity of anxiety and depressed mood was
mild to moderate.
In the acute phase, there was a statistically significant
mean reduction (improvement) versus placebo on each
MFI domain scale rating and BPI average pain measures
at weeks 4, 8, and 12 (Figure 1). In addition, there was a
statistically significant improvement versus placebo in
patient ratings of anxiety, depressed mood, and musculos-
keletal stiffness at weeks 4, 8, and 12 (Figure 2), but ratings
of being bothered by sleep difficulties were significant at
weeks 4 and 8 only. In both treatment groups, acute-phase
mean reductions from baseline in MFI scale ratings in
patients who were pain responders were 2 to 3 points
lower on average (showing improvement in fatigue) com-
pared with a less than 1 point decrease in patients who
were non-responders (Table 1). Acute-phase mean
changes from baseline in MFI scale ratings in patients
with acute-phase endpoint PGI-I ratings of not greater
than 2 were at least two to three times greater than the
mean changes in patients with endpoint PGI-I ratings of
greater than 2, regardless of treatment received (Table 2).
Mean changes at endpoint in MFI scale ratings in patients
who had a dose escalation are summarized in Table 3. A
total of 122 patients not responding to duloxetine 60 mg
were escalated to the 90 mg dose. Those patients who
responded to the 90 mg dose (n = 59) experienced further
reductions (improvement) across the MFI fatigue domains.
Those patients who did not respond to the 90 mg dose
and were escalated to the 120 mg dose (n = 63) experi-
enced minimal improvement.
At the end of the acute phase, 363 patients entered
the 12-week extension phase, and all of them received
double-blind treatment with duloxetine. Patients who
received duloxetine in the acute phase continued on
their stable dose of 60, 90, or 120 mg QD in the exten-
sion phase and were referred to as the duloxetine/dulox-
etine group (n = 176). Patients in the placebo group
(n = 187) who continued in the extension phase
received duloxetine 60 mg QD and were referred to as
the placebo/duloxetine group. Extension-phase baseline
(week 12) and mean changes at study endpoint (week
24) on each secondary measure are summarized in
Table 4. For patients with 24 weeks of treatment with
duloxetine, there were continued statistically significant
within-group improvements in MFI General Fatigue and
Reduced Motivation, BPI average pain, and patient rat-
ings of anxiety, depressed mood, ‘bothered by sleep diffi-
culties’, and musculoskeletal stiffness. Placebo patients
who were transitioned to duloxetine also experienced
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treatment there were statistically significant within-
group improvements observed for all but MFI Mental
Fatigue and Reduced Motivation.
There were no significant between-treatment differ-
ences in the occurrence of fatigue-related treatment-
emergent adverse events during the acute phase of the
study, and these events became less frequent during the
extension phase (Table 5). The most common events
were fatigue, insomnia, and somnolence.
Discussion
Treatment of fatigue has become an important compo-
nent of the overall management of fibromyalgia because
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Figure 1 Reduction (mean changes) from baseline in Multidimensional Fatigue Inventory domains and Brief Pain Inventory (BPI)
average pain severity. Comparisons versus placebo: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. DLX, duloxetine; PLA, placebo.
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bothersome and contributes to reduced quality of life
[4,17,18]. Assessing fatigue is possible with a single
question; however, the type of response a patient gives
would depend on the nature of the question and what
kind of fatigue is being experienced by the patient at
that time. The MFI provides more in-depth information
across five domains, each of which has been validated
against a single global fatigue question, such as the
‘Tiredness’ question on the Fibromyalgia Impact Ques-
tionnaire [19]. Each domain was significantly associated
with this global fatigue question, and this supports the
notions that fatigue is multidimensional and that differ-
ent aspects of fatigue should be measured separately
[20]. Because patients with fibromyalgia often report
fatigue symptoms that are physical as well as mental in
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Figure 2 Reduction (mean changes) from baseline in depressed mood, anxiety, ‘bothered by sleep difficulties’, and musculoskeletal
stiffness. Comparisons versus placebo: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. DLX, duloxetine; PLA, placebo.
Table 1 Mean changes in Multidimensional Fatigue Inventory ratings in pain responders and non-responders
Multidimensional Fatigue Inventory Responders Non-responders
Duloxetine
(n = 140)
Placebo
(n = 103)
Duloxetine
(n = 105)
Placebo
(n = 150)
Mean change (SD) Mean change (SD) Mean change (SD) Mean change (SD)
General Fatigue -3.4 (3.8) -2.8 (3.4) -0.7 (3.3) -0.4 (2.8)
Mental Fatigue -3.0 (4.4) -1.8 (3.6) -0.9 (3.6) -0.5 (3.2)
Physical Fatigue -3.1 (3.9) -2.7 (3.2) -0.6 (2.7) -0.3 (2.9)
Reduced Activity -2.6 (4.0) -1.7 (3.6) -0.2 (3.3) 0.2 (3.4)
Reduced Motivation -2.7 (3.3) -1.6 (3.3) -0.6 (3.1) -0.4 (3.2)
Pain response was defined as an at least 50% reduction from baseline in Brief Pain Inventory average pain severity. A last-observation-carried-forward analysis
was conducted during the acute phase. SD, standard deviation.
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of duloxetine across several dimensions of fatigue.
In this study, mean MFI scale ratings at baseline were
nearly twice as severe as those reported for healthy indi-
viduals in a large US population, whose ratings were all
less than 9 points [21]. The severity of fatigue in the
patients with fibromyalgia in the present study was clini-
cally significant because each MFI domain rating was
more than 3 points higher than those of healthy indivi-
duals [21]. Furthermore, the MFI domain ratings in these
patients were as severe as those reported by others for
fibromyalgia [20] as well as patients with other chronic
diseases like chronic fatigue syndrome [21], Sjögren syn-
drome [22], and chronic low back pain [23] and cancer
patients receiving radiation therapy [24].
Treatment with duloxetine versus placebo significantly
improved fatigue across all of the MFI domains within 4
weeks and continued to improve at each visit thereafter,
and improvement was maintained for up to 24 weeks. The
magnitude of improvement across the MFI domains was
similar (reduction of about 2 points each), and this sug-
gests that treatment with duloxetine improves not only
global fatigue symptoms but also both physical and mental
aspects of fatigue. Across acute-phase treatment groups,
patient global impression of feeling at least ‘much better’
was associated with a 2- to 3-point decrease in fatigue
severity across MFI domains, suggesting that improvement
in fatigue may be as important as improvement in pain in
this patient population. Previous studies have suggested
that there is an association between pain and fatigue. For
instance, changes in pain and fatigue in patients with
fibromyalgia have been found to be moderately correlated
with patient ratings of feeling ‘better’ [25]. In addition, a
review of studies in patients with various chronic pain dis-
ease states reported that fatigue decreases when pain
improves [26]. Also, pain was noted to be a predictor of
fatigue in patients with rheumatoid arthritis, osteoarthritis,
or fibromyalgia [27], and individuals with greater pain
severity report greater fatigue [23]. In the present study,
improvement in fatigue across MFI domains was two to
three times greater in patients who were pain responders
compared with non-responders. In addition, duloxetine 90
mg QD was associated with further reduction in pain [14]
and improvement across fatigue domains for those
patients who responded to this dose.
Treatment with duloxetine was associated not only
with reduction in pain and fatigue in this study but also
with reduction in severity of anxiety, depressed mood,
‘bothered by sleep difficulties’, and musculoskeletal stiff-
ness. Changes in these symptoms may have contributed
to the improvement observed in fatigue because, across
all of these measures, with the exception of ‘bothered by
sleep difficulties’ for which the mean change at week 12
did not separate from placebo (P = 0.06), significant
Table 2 Mean changes from baseline in Multidimensional Fatigue Inventory ratings in patients with PGI-I of not more
than 2 or greater than 2
Multidimensional Fatigue Inventory PGI-I ≤ 2 PGI-I > 2
Duloxetine
(n = 114)
Placebo
(n = 64)
Duloxetine
(n = 132)
Placebo
(n = 189)
Mean (SE) Mean (SE) Mean (SE) Mean (SE)
General Fatigue -3.8 (0.4)
a -4.2 (0.5)
a -0.9 (0.3)
a -0.4 (0.2)
Mental Fatigue -3.1 (0.4)
a -3.1 (0.5)
a -1.1 (0.3)
a -0.5 (0.3)
Physical Fatigue -3.6 (0.4)
a -3.7 (0.5)
a -0.8 (0.3)
a -0.7 (0.3)
a
Reduced Activity -3.2 (0.4)
a -3.0 (0.5)
a -0.2 (0.3) 0.2 (0.3)
Reduced Motivation -2.9 (0.4)
a -2.9 (0.5)
a -0.7 (0.3)
a -0.1 (0.3)
aStatistically significant (P ≤ 0.05) within-group change from baseline to endpoint at acute-phase endpoint (week 12). A last-observation-carried-forward analysis
was conducted. PGI-I, Patient Global Impression of Improvement; SE, standard error.
Table 3 Multidimensional Fatigue Inventory ratings in patients who were escalated to a higher duloxetine dose
Multidimensional Fatigue Inventory Duloxetine 90 mg
(n = 59)
a
Duloxetine 120 mg
(n = 63)
b
Rating before escalation Endpoint Rating before escalation Endpoint
Mean (SD) Mean change (SD) Mean (SD) Mean change (SD)
General Fatigue 15.3 (3.4) -0.7 (3.6) 16.0 (3.1) -0.2 (3.0)
Mental Fatigue 12.1 (4.6) -0.9 (3.0) 11.7 (4.0) 0.1 (3.3)
Physical Fatigue 14.6 (3.9) -1.3 (3.7) 14.2 (3.6) 0.1 (2.6)
Reduced Activity 12.8 (4.3) -1.0 (3.5) 12.8 (4.2) 0.2 (3.1)
Reduced Motivation 11.4 (3.9) -1.1 (3.3) 11.5 (3.5) -0.1 (3.1)
aPatients who responded to duloxetine 90 mg QD.
bPatients who did not respond to the 90 mg dose and were escalated to 120 mg. A last-observation-carried-
forward analysis was conducted at acute-phase endpoint (week 12). SD, standard deviation.
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when LOCF analysis was used, ‘bothered by sleep diffi-
culties’ reported in the primary analysis of this study was
significantly improved with duloxetine treatment as com-
pared with placebo (P = 0.05) [14]. Overall, these findings
are consistent with a study that found that a moderate
(30% to 50%) to substantial (> 50%) reduction in pain
was associated with significant reductions in fatigue,
sleep disturbance, depression, and anxiety in patients
with fibromyalgia [28].
Several limitations to the present study may impact the
interpretation of the results. First, a specified level of fati-
gue severity was not required for patients to be included
in this study. In addition, the results of this study may
not be generalizable to patients with some psychiatric
comorbid disorders or unstable medical or comorbid
pain disorders or to patients who were treatment-refrac-
tory or disabled, because patients with these conditions
were excluded from the study. Lastly, the results of this
study do not definitively show the relationship between
fatigue and any of the other symptoms of fibromyalgia;
this relationship requires further research.
Conclusions
Fatigue is a common and often disabling symptom asso-
ciated with fibromyalgia. The MFI is a measure that
captures the multidimensional nature of fatigue that is
experienced by patients with fibromyalgia. This second-
ary analysis provides evidence for the efficacy of duloxe-
tine in improvements in multidimensional fatigue
domains across 24 weeks of treatment.
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